Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53
- 25 January 2001
- journal article
- Published by Springer Nature in Oncogene
- Vol. 20 (4) , 514-522
- https://doi.org/10.1038/sj.onc.1204118
Abstract
Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.Keywords
This publication has 32 references indexed in Scilit:
- Different p73 splicing variants are expressed in distinct tumour areas of a multifocal neuroblastomaCell Death & Differentiation, 1999
- Loss of imprinting and allele switching of p73 in renal cell carcinomaOncogene, 1998
- Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.Journal of Clinical Investigation, 1997
- The Spectrum of Mutations at the p53 LocusAnnals of the New York Academy of Sciences, 1995
- Induction of apoptosis in HeLa cells by trans-activation-deficient p53.Genes & Development, 1995
- The regulation of p53 function: Steiner award lectureInternational Journal of Cancer, 1994
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- Biological Activities of p53 Mutants in Burkitt's Lymphoma CellsJournal of General Virology, 1993
- Epstein--Barr virus (EBV) nuclear antigen 6 induces expression of the EBV latent membrane protein and an activated phenotype in Raji cellsJournal of General Virology, 1993
- Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.Genes & Development, 1992